TR35 | What are these talented people on the list? (on)

A few days ago, "MIT Technology Review" released the 35 "35 Innovators Under 35" winners of the 35-year-old innovators in 2016. The winners included artificial intelligence, robotics, and biomedical technology. Following, Lei Feng Network (search "Lei Feng Net" public concern) summed up the bio-medical technology entrepreneurs, humanitarians, see Yin Si Qi. They graduated from a prestigious school, or tirelessly or willing to work hard to contribute their knowledge and talents to society and humanity:

entrepreneur

Heather Bowerman, 31, CEO of Dot Laboratories

Reasons for inclusion: Creating low-cost hormone testing technology to address gender differences in drug and disease treatment, and promoting women's health

Heather Bowerman is the CEO of Dot Laboratories, a medical technology company that aims to develop inexpensive and rapid female hormone detection technology. Users only need to save a little saliva at a certain time and mail it to Dot Laboratories. The company can analyze the hormone level and return the results to users and doctors through the Internet. The technology is still in the test period. The company plans to launch the testing service in 2017.

Heather Bowerman said: "Women's response to diseases and drugs is significantly different from that of men in many cases, but so far there is no effective treatment for women in the world." For example, hormone differences lead to different platelet properties in men and women, but cardiovascular disease Drugs are primarily directed at the physiological response of men, so the effect of drugs on men is significantly greater than that of women. A detailed examination of the hormonal properties helps doctors design targeted drugs and treatments for women.

Heather Bowerman graduated from the University of California, Berkeley, with a bachelor's degree in bioengineering and later received a master's degree from Harvard Medical School. Prior to joining Dot Labs, Bowerman was an operating consultant with McKinsey & Co. Consulting and a partner in the White House’s Office of Science and Technology Policy (OSTP). During her time at the White House, she focused on the "US Innovation Strategy" and the government's legislative "US Invention Act" focused on technology.

After graduation, Bowerman trained as a teaching assistant in the Harvard Graduate Nanotechnology graduate course. Earlier in his career, Bowerman worked for a private equity fund in New York and led the acquisition of a portable molecular diagnostics company whose core technology could fight the H5N1 and H1N1 virus epidemics.

Kelly Gardner, 31, CEO of Zephyrus Biosciences

Reasons for inclusion: Development of single-cell protein testing technology to promote the diagnosis and treatment of cancer

Kelly Gardner is the CEO of Zephyrus Biosciences, a biotechnology startup that aims to develop single-cell protein detection technology to help improve the diagnosis and treatment of diseases. According to Kelly Gardner, proteins are the basic components of cells. Measuring the level of cellular proteins plays an important role in the diagnosis and treatment of diseases. However, due to the lack of protein amplification technology in the current state of the art, the sample size is very poor, resulting in protein testing more difficult than DNA testing. However, the detection of single-cell proteins can play a very important role in the diagnosis and treatment of cancer, so it is of great significance.

Before starting the product development, Zephyrus Biosciences negotiated with 100 biomedical researchers to analyze the technology that users are interested in, and finally determined to carry out single cell protein detection technology research and development. At present, the company draws on the IT company's operating model and uses the mode of light riding and flat posts to obtain flexible and rapid operations. It only raises $1.8 million in funds and employs only a few people.

Kelly Gardner graduated from Yale University with a bachelor's degree in biomedical and mechanical engineering. He then completed a master's degree in biological sciences at Cambridge University and received a doctorate in bioengineering from the University of California. He has published several research articles on protein medicine. She considers herself a natural entrepreneur and before founding Zephyrus Biosciences, Kelly Gardner founded the autotech company AutoTB. During her career, she was a postgraduate researcher at the University of California, Berkeley, NSF, and director of marketing at ProteinSimple, the United States.

Humanitarian

Jagdish Chaturvedi, 32, clinical research leader at InnAccel

Reason for selection: Invented the Entraview inspection system, benefiting 200,000 patients with throat diseases

Jagdish Chaturvedi used to be a doctor and is currently the clinical research leader of InnAccel, a medical technology incubator. He invented Entraview, a low-cost ear, nose, and throat imaging device. Jagdish Chaturvedi said: “When I was doing an internship, I saw many farmers suffering from advanced throat cancer. I realized that only big cities have professional imaging inspection systems, not to mention expensive prices, so rural doctors can only Relying on obsolete mirrors and headlamps. When I asked the boss why no one tried to connect an endoscope to a small general-purpose camera, the boss encouraged me, 'Why can't you do it?'

Sonia Vallabh, 32, a prion specialist at the Broad Institute

Reasons for inclusion: Turning from the legal profession to medical research to find a cure for hereditary prion diseases

Sonia Vallabh graduated from Harvard Law School five years ago and worked as a staff member at a small consulting firm. However, her fate was changed by a medical certificate.

In 2010, Sonia Vallabh married her husband when her healthy mother ran this wonderful wedding. However, shortly after the wedding, Sonia Vallabh’s mother was getting thinner and she died. An autopsy report told Sonia Vallabh that her mother’s cause was a mutation in the DNA sequence that caused a fatal hereditary prion disease. More unfortunately, after several months of inspection, Sonia Vallabh found the same pathogenic variation in his genome. The patient carrying the virus can live to 50 years old and then suddenly fall into dementia and die within a year. Moreover, there is currently no drug to cure the disease.

"This cruel fact has made us stronger. We have begun to think of ways to deal with this enemy." Sonia Vallabh has done everything in his power to learn relevant knowledge and is committed to the study of hereditary prion diseases. She attended night school, participated in international conferences, and even eventually participated in research work in the laboratory. To this day, Sonia Vallabh has been adhering to it for four years. "I know the road ahead is full of uncertainty. A lot of hard work will not guarantee that we can find effective treatments. But we will do our best to unite with the creative forces in various fields. Get up and find a cure that will save me and save more lives.”